首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 62 毫秒
1.
目的 ROC曲线分析探讨前列腺特异性抗原密度(PSAD)、总PSA(tPSA)和游离PSA/总PSA(fPSA/tPSA)3者在PSA灰区前列腺癌(PCa)中的临床诊断价值.方法 同顾性分析tPSA在4~10ng/ml之间的前列腺增生(BPH)患者75例和前列腺癌患者31例.化学发光法测定血清tPSA和fPSA,经直肠超声(TRUS)测定前列腺体积,计算fPSA/tPSA和PSAD.比较BPH组和PCa组间tPSA、PSAD和fPSA/tPSA各指标的差异,分析各指标在ROC曲线卜的面积、各指标的诊断特异性及敏感性.结果 PCa组与BPH组tPSA差异无统计学意义(P>0.05),PCa组fPSA/tPSA比值较BPH组降低(P<0.01),PSAD值较BPH组升高(P<0.05).ROC曲线下的面积从大到小为fPSA/tPSA>PSAD>tPSA.在诊断敏感性相同的情况下,fPSA/tPSA比值诊断特异性高于PSAD的诊断特异性.当fPSA/tPSA临界值取0.16时,诊断前列腺癌的灵敏度和特异性为67.7%和79.7%,PSAD临界值取0.12时,其灵敏度和特异性为61.3%和62.7%.结论 当tPSA在诊断灰区时,PSAD和fPSA/tPSA可以提高前列腺癌的诊断特异性和敏感性,fPSA/tPSA较PSAD有更高的诊断价值.  相似文献   

2.
目的:探讨Ⅳ型前列腺炎炎症组织病理学分级和范围与前列腺特异性抗原(PSA)的关系。方法:对120例临床可疑前列腺癌患者采用B超引导下经会阴前列腺穿刺病理活检,排除前列腺癌及不合并炎症的前列腺增生病例,仅BPH合并前列腺炎病例入选,采用NIH-Ⅳ型前列腺炎组织病理学分类方法对每例患者标本按炎症位置、范围和分级3方面分3级比较,评价炎症与血清PSA的关系。结果:120例患者中BPH合并前列腺炎症46例。①组织病理学炎症范围分级,1级35例,2级7例,3级4例,tPSA分别为(8.46±4.09)μg/L、(15.26±5.26)μg/L和(21.05±7.58)μg/L,fPSA分别为(1.75±0.93)μg/L、(2.54±0.72)μg/L和(3.19±1.13)μg/L,PSAD分别为0.15±0.11、0.26±0.07和0.42±0.19。三级之间比较tPSA(P=0.001)、fPSA(P=0.008)和PSAD(P<0.001)差异均具有显著性。②组织病理学炎症分级,1级32例,2级10例,3级4例。tPSA分别为(8.37±4.07)μg/L、(13.30±5.69)μg/L和(21.05±7.58)μg/L。fPSA分别为(1.76±0.93)μg/L、(3.27±2.21)μg/L和(3.19±1.13)μg/L。PSAD分别为0.14±0.11、0.25±0.06和0.42±0.19。三级之间比较tPSA(P=0.002)、fPSA(P=0.024)和PSAD(P<0.001)差异均有显著性。③组织病理学炎症位置分级,1级19例,2级17例,3级10例,三级之间tPSA、fPSA、%fPSA差异均无显著性(P>0.05)。④组织病理学炎症范围与tPSA(r=0.6,P<0.001)、fPSA(r=0.5,P=0.001)和PSAD(r=0.6,P<0.001)呈显著正相关关系。组织病理学炎症分级与tPSA(r=0.5,P<0.001)、fPSA(r=0.4,P=0.008)和PSAD(r=0.7,P<0.001)呈显著正相关关系,与%fPSA呈显著负相关关系(r=-0.4,P=0.013)。结论:无症状前列腺炎症患者组织病理学炎症的分级和范围与血PSA显著相关,病理医生应对前列腺穿刺标本进行炎症描述,其对高分级前列腺炎症患者可避免反复活检。  相似文献   

3.
目的:综合利用PSA及其相关参数建立能够简便查询的前列腺穿刺阳性率查询表.方法纳入2009年7月至2015年3月在解放军总医院行前列腺穿刺活检的患者,收集前列腺体积、游离PSA(free PSA,fPSA)和总PSA(total PSA,tPSA)等临床资料.多因素Logistic回归分析预测前列腺癌的独立性影响因素,并利用相关因素建立前列腺穿刺阳性结果查询表.结果资料完整且病理结果为前列腺癌和前列腺增生的患者纳入研究,共1077例.根据PSA水平分为0~2.5、2.6~4.0、4.1~10.0、10.1~20.0和>20.0 ng/ml 5组,前列腺癌检出率分别为20.9%、20.0%、37.3%、48.1%和80.2%,随着PSA水平的升高,前列腺癌检出率也明显升高.多因素Logistic回归分析发现tPSA、fPSA和前列腺体积均为前列腺癌的独立性预测因素,tPSA、fPSA百分比(free to total PSA,f/tPSA)和PSA密度(PSA density,PSAD)在前列腺癌和前列腺增生两组间存在显著差异(P<0.05),综合利用上述3个指标建立前列腺阳性穿刺查询表.结论本研究根据 tPSA、f/tPSA和PSAD建立的查询表为临床前列腺穿刺活检提供了一个简便实用的阳性率查询工具.  相似文献   

4.
目的探讨血清性激素在前列腺癌(PCa)诊断中的作用价值及与前列腺特异性抗原(PSA)的关系。方法 PCa患者30例、良性前列腺增生症(BPH)患者45例及正常人45例,检测睾酮(T)、雌二醇(E2)、孕酮(P)、卵泡刺激素(FSH)、黄体生成素(LH)及泌乳素(PRL)和PSA的水平。比较各组间性激素及PSA的差异。分析性激素及PSA对PCa的诊断价值及两者的相关性。结果 PCa组中T降低明显,FSH、LH增高明显;总PSA(tPSA)、游离PSA(fPSA)、PSA密度(PSAD)增高明显,fPSA与tPSA比值(f/tPSA)降低明显。tPSA、fPSA、PSAD、T、FSH、LH的ROC曲线下面积(AROC)分别为1.000、0.894、0.991、0.920、0.753、0.868;各检测参数AROC比较,tPSA和PSAD、fPSA和T、fPSA和LH、PSAD和T、T和LH、FSH和LH配对比较差异无统计学意义(P0.05),余配对比较差异有统计学意义(P0.05)。相关性分析结果显示,PCa患者tPSA与T有相关性(P0.05),与E2、P、FSH、LH及PRL水平无相关性(P0.05)。结论 PCa患者T水平降低,FSH、LH水平增高。PCa患者PSA与血清T有相关性,T、FSH和LH对早期PCa具有与tPSA、f/tPSA和PSAD接近相同的诊断能力。血清PSA联合性激素T、FSH和LH检测有助于PCa的早期诊断。  相似文献   

5.
目的 探讨抗炎治疗后亚临床型前列腺炎患者血清PSA变化及其临床意义.方法 直肠指检阴性的亚临床型前列腺炎患者136例.实验窒检查PSA 4.2~49.7(14.0±7.8)ng/ml.136例予抗炎治疗后2周复查PSA并在B超引导下行前列腺穿刺活检.评估抗炎治疗前后PSA、PSA密度(PSAD)、游离/结合PSA(f/t PSA)及其变化(△PSA、△PSAD、△f/t PSA),受试者工作特征(ROC)曲线分析抗炎前后各参数对前列腺癌的诊断效力.采用SPSS 11.0软件对组间行t检验.结果 136例穿刺活检诊断为前列腺癌33例.良性病变103例.抗炎治疗前后相比:PSA由(14.0±7.8)ng/ml降至(10.4±7.7)ng/ml、PSAD从(0.24±0.12)ng·ml1·ml~(-1)降至(0.18±0.12)ng·ml~(-1)·ml 1、f/t PSA从0.23±0.08降至0.16±0.07,治疗前后比较差异均有统计学意义(P<0.05).△PSA、△PSAD和△f/tPSA分别为(-3.59±4.34)ng/ml、(-0.10±0.09)ng·ml-1·ml-1及-0.06±0.05.抗炎治疗前PSA、PSAD和f/t PSA诊断前列腺癌ROC曲线下面积分别为0.288、0.642和0.504,△PSA、APSAD和△f/tPSA诊断前列腺癌ROC曲线下面积分别为0.910、0.957和0.983,与治疗前比较差异均有统计学意义(P值均<0.01).结论 亚临床型前列腺炎伴有PSA增高者经抗炎治疗2周后血清PSA明显下降;利用抗炎治疗后△PSA、APSAD、△f/t PSA可提高前列腺癌的诊断率,减少不必要的前列腺穿刺活检.  相似文献   

6.
目的分析前列腺特异抗原(PSA)及其相关参数诊断前列腺癌的能力,并利用本数据验证解放军总医院所建立的列线图模型(301模型)。方法 2010年1月至2015年6月,233例患者在我院行经直肠前列腺穿刺或前列腺电切术,回顾性分析其临床资料,其中前列腺癌95例,前列腺增生患者138例。利用受试者工作特征曲线(ROC)评价游离PSA百分比(f/tPSA)、PSA密度(PSAD)及(f/t)/PSAD对前列腺癌的诊断价值。结果在PSA10.1~20.0ng/mL和20ng/mL范围内,f/tPSA、PSAD及(f/t)/PSAD三者在两组患者间均有差异(P0.05)。在tPSA 10.1~20ng/mL范围内,301模型的ROC曲线下面积显著高于f/tPSA(P0.05),而与PSAD、(f/t)/PSAD之间差异无统计学意义(P0.05);PSAD的ROC曲线下面积高于f/tPSA(P0.05),与(f/t)/PSAD之间无明显差异(P0.05),f/tPSA和(f/t)/PSAD之间差异无统计学意义(P0.05)。而在tPSA20ng/mL组中,301模型明显低于其他指标(P0.05),而f/tPSA、PSAD及(f/t)/PSAD三者间ROC曲线下面积无明显差异(P0.05)。结论 f/tPSA、PSAD及(f/t)/PSAD均有助于提高前列腺癌的检出率,(f/t)/PSAD的诊断效能受f/tPSA和PSAD的影响;在tPSA 10.1~20.0ng/mL范围内,301模型比其他指标具有更高的预测前列腺癌准确性。  相似文献   

7.
目的 探讨ALP、PSA及其相关指标(fPSA、fPSA/tPSA、PSAD)与前列腺癌骨转移的关系,及对前列腺癌骨转移诊断的预测作用.方法 回顾分析2005年9月至2009年2月在我院经前列腺穿刺活检或手术后病理检查确诊的167例前列腺癌患者.以ECT、X线片、CT/MRI或骨活检诊断骨转移,分析ALP、PSA、fPSA、fPSA/tPSA、PSAD与前列腺癌骨转移的关系及对骨转移的诊断价值.结果 167例前列腺癌患者中骨转移104例(62.3%),非骨转移63例(37.7%).骨转移组ALP、PSA及PSAD明显高于非骨转移组(均P<0.01),而两组间fPSA/tPSA差异无统计学意义(P>0.05).PSA>50 ng/ml组骨转移率明显高于PSA>20~50 ng/ml组、>10~20 ng/ml组和≤10 ng/ml组(均P<0.05);ALP>90 U/L组骨转移率明显高于ALP≤90 U/L组(P<0.05);PSAD>0.4 ng·ml-1·cm-3组骨转移率明显高于PSAD≤0.4 ng·ml-1·cm-3组(P<0.05).以ALP>90 U/L、PSA>50 ng/ml和PSAD>0.4 ng·ml-1·cm-3为界分别分析ALP、PSA、PSAD、PSA+ALP、PSA+PSAD和PSA+PSAD+ALP对前列腺癌骨转移诊断的预测价值,发现指标联合应用后阳性预测值及阴性预测值较单一指标好,PSA+PSAD+ALP联合应用的敏感度、特异度、阳性预测值及阴性预测值最佳,分别为100%、79.17%、91.38%及100%.结论 ALP、PSA及PSAD均为判断前列腺癌患者有无骨转移的可靠指标,PSA+PSAD+ALP联合应用有助于预测前列腺癌骨转移,当患者PSA<50 ng/ml、PSAD<0.4 ng·ml-1·cm-3及ALP<90 U/L时,几乎可排除骨转移.  相似文献   

8.
目的 探讨在前列腺特异抗原(prostate specific antigen,PSA)灰区(PSA 4~10ng/mL)患者中,血清总PSA及游离PSA比值(f/tPSA)、前列腺特异性抗原密度(PSAD)和(f/t) PSA/PSAD值对穿刺病理结果的诊断价值.方法 回顾2008年1月至2016年3月本院接受经直肠超声(transrectal ultrasound,TRUS)引导下前列腺穿刺的患者929例,对其中249例PSA 4~ 10 ng/mL患者的临床资料进行了整理分析.根据病理结果,分为前列腺癌组(PCa组)38例(15.26%),前列腺增生组(BPH组)211例(84.74%).对患者年龄、tPSA、f/tPSA、体积、PSAD、(f/t) PSA/PSAD值进行统计学分析.结果 两组患者的年龄水平比较差异无统计学意义(P>0.05);在f/tPSA、体积、(f/t) PSA/PSAD水平,BPH组大于PCa组;在tPSA、PSAD水平,PCa组大于BPH组,差异均有统计学意义(P<0.05).PCa组患者中f/tPSA或PSAD异常者32例,占84.21%:BPH组中f/tPSA或PSAD异常者110例,占52.13%,差异有统计学意义(X2=13.52,P <0.005).结论 f/tPSA和PSAD异常对PSA灰区的患者是否行前列腺穿刺具有指导意义.如果f/tPSA和PSAD结果相矛盾,f/tPSA联合PSAD、PSAD联合(f/t) PSA/PSAD的诊断价值相对较高.  相似文献   

9.
目的 基于单中心数据资料探讨不同前列腺体积计算方式对前列腺特异性抗原密度(PSAD)诊断前列腺癌准确性的影响。方法 收集解放军联勤保障部队第九八○医院2016年10月至2019年8月行前列腺穿刺活检患者的临床及病理资料,包括年龄、前列腺上下径(L)、左右径(W)和前后径(H)、游离PSA(fPSA)、总PSA(tPSA)。纳入tPSA在4~10ng/mL范围且资料完整患者291例。根据不同的公式计算前列腺体积(PV),椭圆形体积计算法:PV=0.52×L×W×H;长椭圆形体积计算法:PV=0.52×H×W2;球形体积计算法:PV1=0.52×H3,PV2=0.52×W3,PV3=0.52×L3。利用配对t检验分析同一患者不同计算方式所得PV的差异。应用各PV计算PSAD,前列腺癌与前列腺增生两组间各PSAD的比较采用t检验,并利用受试者工作特征曲线(ROC)评估不同PSAD对前列腺癌的诊断价值。结果 本研究291例病理结果:前列腺增生172例,前列腺癌119例。比较同一患者不同计算方式所得PV(cm3):PV椭圆(57.6±38.3),PV长椭圆(63.3±35.7),PV球形1(46.5±39.6),PV球形2(77.9±38.7),PV球形3(60±51.2),发现各前列腺体积之间均存在明显差异(P0.05)。在总PSA 4~10ng/mL患者中,每一种计算方式所得PSAD在前列腺癌与前列腺增生两组间均存在明显差异(P0.05),且Z检验表明各PSAD的ROC曲线下面积(PSAD椭圆:0.857,PSAD长椭圆:0.842,PSAD球形1 0.842,PV球形2:0.795,PV球形3:0.853)并无明显差异(P0.05)。PSAD椭圆和PSAD球3明显高于f/tPSA(0.771)(P0.05),其他PSAD与f/t间无明显差异(P0.05)。结论 本研究基于单中心数据发现虽然利用不同计算公式所得到的前列腺体积之间存在差异,但其计算的PSAD在tPSA 4~10ng/mL患者中,对前列腺癌具有相似的诊断价值,并无明显差异。  相似文献   

10.
目的:探讨前列腺特异性抗原(PSA)测定在有下尿路症状的良性前列腺增生(BPH)患者的临床意义。方法:比较520例有症状和196例无症状的BPH患者的总PSA(tPSA),游离PSA(fPSA)和fPSA/tPSA等指标,并进行统计学分析。结果:有症状组和无症状组的tPSA值分别为(5.13±2.49)、(1.73±1.26)μg/L,差异有极显著性(P<0.01);fPSA分别为(1.57±0.80)、(0.54±0.38)μg/L,差异有极显著性(P<0.01);fPSA/tPSA分别为0.31±0.09和0.30±0.11,差异无显著性(P>0.05)。结论:有下尿路症状BPH患者的tPSA、fPSA明显高于无症状,但fPSA/tPSA比值在BPH患者中稳定。  相似文献   

11.
Summary In benign hyperplasia marked -glucuronidase and N-acetyl--glucosaminidase activity was seen in the prostatic epithelium whereas the reactions for 5 other glycosidases were only slight or negative. The intensity of the reaction for the glycosidases in prostatic carcinoma was dependent upon the degree of the differentiation. The possible importance of glycosidases for the invasiveness of prostatic carcinoma is briefly discussed.  相似文献   

12.
ObjectivesThe objective of this paper is to examine the contemporary incidence, diagnosis, and treatment of prostatic urothelial carcinoma and make recommendations on the current dilemmas of treating urothelial cancer of the prostate.MethodsA review of English-language literature from 1990 to the present was performed utilizing the U.S. National Library of Medicine's Pub Med database. Keywords used were urothelial cell carcinoma, prostatic urethral involvement, prostatic duct/acini involvement, carcinoma in situ. Bibliographies of reviewed articles were also searched.ResultsTransitional cell carcinoma of the bladder with involvement of the prostate has been reported in multiple studies with an incidence between 12% and 48%. Stromal invasion of the prostate has a reported incidence between 7% and 17%. The incidence of primary transitional cell carcinoma of the prostate has been estimated at 1% to 4% of prostatic malignancies. Degree and depth of prostatic invasion has prognostic significance with 5-year survival rates being 100% for those with urethral mucosal involvement, 50% with ductal/acinar involvement, and 40% with prostatic stromal invasion. The actual anatomic path that urothelial carcinoma invasion occurs also has prognostic significance. Those with contiguous malignant involvement had a 7% 5-year survival rate compared with those with noncontiguous involvement and a 46% 5-year survival rate.ConclusionsProstatic urothelial carcinoma is often under appreciated and not well understood. Malignant involvement of different anatomic locations of the prostate (i.e., mucosa, ducts, acini, and stroma) influence not only diagnosis but treatment of disease. Although debate exists regarding optimal therapy for mucosal involvement, if the prostatic stroma is involved, radical cystoprostatectomy is the treatment of choice.  相似文献   

13.
PSA及PSAD测定对前列腺癌的诊断价值   总被引:14,自引:1,他引:13  
应用双抗体夹心酶标免疫法对无选择性201例无明显良性前列腺增生(BPH)症状的45岁以上男性进行血清前列腺特异抗原(PSA)及前列腺特异抗原密度(PSAD)测定,并以慢性前列腺炎14例,BPH已作前列腺切除11例作为对照。结果发现:PSA随年龄增大而增高,至70岁以后未再继续增高。PSA>4μg/L者22例,其中11例在B超引导下作前列腺穿刺活检,10例为BPH,1例为前列腺癌。PSA及PSAD对鉴别BPH与前列腺癌价值不大,BPH手术后PSA逐步下降至正常  相似文献   

14.
目的 探讨经腹剪切波成像(shear-wave,SWV)技术对前列腺良恶性病变诊断的临床价值.方法 应用SWV技术对60例前列腺占位性病变患者进行检查,测值与术后病理结果对照,鉴别其良恶性.结果 SWV技术检测的前列腺恶性占位病变与前列腺良性占位病变组比较,剪切波速差异有统计学意义(P<0.01);前列腺良性占位与前列腺正常组的剪切波速比较差异具有统计学意义(P<0.017).以剪切波速大于2.87 m/s作为前列腺恶性占位的诊断标准,SWV鉴别前列腺良恶性占位的敏感性为80.0%,特异性为66.7%.结论 SWV技术可以为前列腺良、恶性病变的筛查提供更多的信息和依据.  相似文献   

15.
Yang Y  Lu J  Hong B  Wang X 《中华外科杂志》1998,36(11):677-678,I134
目的 探讨前列腺软斑病的诊断和治疗方法,方法 报告2例前列腺软斑病并综合文献复习对其病因,发病机制,临床表现,诊断等进行分析。结果 前列腺软斑病多与感染及免疫障碍有关,是可治愈的炎性病变,但临床上易与前理腺癌相混澹而行根治性前列腺切除术。结论 前列腺穿刺活检及抗炎治疗是诊治前列腺软斑病的可靠方法。  相似文献   

16.
目的 探讨Ku80蛋白表达与前列腺癌血清PSA和前列腺癌Gleason分级之间的关系.方法 采用HE染色观察前列腺癌组织学形态并进行分级,免疫组化SP法检测前列腺癌组织中Ku80蛋白表达,按前列腺癌Gleason评分和血清PSA值分组,比较各组间Ku80蛋白表达水平.结果 58例前列腺癌标本中Ku80蛋白均呈阳性表达,伴随着前列腺癌Gleason评分和血清PSA值升高,Ku80蛋白表达强度明显增强.结论 Ku80蛋白表达水平能预测前列腺癌预后及治疗效果,可用于临床指导个体化治疗.  相似文献   

17.
PAP和PSA与前列腺癌诊治的关系   总被引:3,自引:0,他引:3  
目的 :探讨前列腺酸性磷酸酶 (PAP)、前列腺特异抗原 (PSA)与前列腺癌的诊断、临床分期、预后判断的关系。方法 :用放射免疫测定法 (RIA)检测经病理检查证实的前列腺癌 5 2例 ,同时以 PAP、PSA辅助诊断。结果 :PSA阳性率明显高于直肠指检、B超和 PAP(P <0 .0 5 )。PAP和 PSA升高与前列腺癌的分期、肿瘤细胞分化程度具有相关性。结论 :PAP和 PSA对前列腺癌的诊断、临床分期、预后判断有较大应用价值  相似文献   

18.
Objective To obtain shRNA sequences that can stably block the expression of Nuclear Factor kappa- B (p65) in the prostate cancer cell line LNCaP and construct the lentivirus vector.And validate the gene function of p65 in the cell line. Methods According to p65 genetic information, we design siRNA1, siRNA2, siRNA3 those three siRNA sequences targeting the ods area of p65 gene and then form the corresponding four pairs of complementary single strand DNA of shRNA, including the sense strand and the antisense strand. The synthetic shRNA sequence was inserted into the empty pSIH1-H1-copGFP shRNA Vector, and after transfecting the prostate cancer cells , the inhibitory effect of p65 mRNA by different sequences was detected through real-time PCR, and the inhibitory effect of p65 protein expression was detected by Western-blotting. Thus we can obtain highly effective shRNA sequences in the inhibition of p65 in prostate cancer cells. MTT, flow cytometry, transwell were chosen to test the cell growth, migration and invasive power in vitro to compare the difference of the experimental group, control group and negative group. Results The third shRNA sequence had the best inhibitory effect and the inhibitory effect of p65 mRNA in prostate cancer cell line was 59 % and the protein was 81%. It's position locates in p65 (NM_021975 ) 1096-1113 and it's stemloop sequence is 5'-GATCCGCCCTATCCCTTTACGTCATTCAAGAGATGACGTAAAGGGATAGGGCTTTTTG-3'. After transfecting, the prostate cancer cell line had the low expression of p65 stably. Through MTT, we got the growth curve, which showed that the growth ability of experimental group was significantly decreased compared with the control group and the Logarithmic growth didn't appear in the first 96 hours. Flow cytometry test displayed that the percentage of G0-G1-phase cells in experimental group was 61.49%, and the control group was 44.89%, idle group was 41.52%, which was increasing oberviously. The S-phase cells in the experimental group was 28.58%, compared with the 47.36% and 46. 10% diminished. The results of transwell showed that the experimental group had 16. 5000±6. 62076 cells and the other two groups had 45. 6333 13. 54159 and 36. 8333±5. 68412 cells, which showed the invasive power of experimental group was significantly declined(P<0.05).Conclusions It's successful to obtain shRNA sequences that can stably block the expression of p65 in the prostate cancer cell line LNCaP and construct the lentivirus vector. p65 can positively regulates the biological behavior of prostate cancer LNCaP cell line in the cell growth, migration and invasive power.  相似文献   

19.
Objective To obtain shRNA sequences that can stably block the expression of Nuclear Factor kappa- B (p65) in the prostate cancer cell line LNCaP and construct the lentivirus vector.And validate the gene function of p65 in the cell line. Methods According to p65 genetic information, we design siRNA1, siRNA2, siRNA3 those three siRNA sequences targeting the ods area of p65 gene and then form the corresponding four pairs of complementary single strand DNA of shRNA, including the sense strand and the antisense strand. The synthetic shRNA sequence was inserted into the empty pSIH1-H1-copGFP shRNA Vector, and after transfecting the prostate cancer cells , the inhibitory effect of p65 mRNA by different sequences was detected through real-time PCR, and the inhibitory effect of p65 protein expression was detected by Western-blotting. Thus we can obtain highly effective shRNA sequences in the inhibition of p65 in prostate cancer cells. MTT, flow cytometry, transwell were chosen to test the cell growth, migration and invasive power in vitro to compare the difference of the experimental group, control group and negative group. Results The third shRNA sequence had the best inhibitory effect and the inhibitory effect of p65 mRNA in prostate cancer cell line was 59 % and the protein was 81%. It's position locates in p65 (NM_021975 ) 1096-1113 and it's stemloop sequence is 5'-GATCCGCCCTATCCCTTTACGTCATTCAAGAGATGACGTAAAGGGATAGGGCTTTTTG-3'. After transfecting, the prostate cancer cell line had the low expression of p65 stably. Through MTT, we got the growth curve, which showed that the growth ability of experimental group was significantly decreased compared with the control group and the Logarithmic growth didn't appear in the first 96 hours. Flow cytometry test displayed that the percentage of G0-G1-phase cells in experimental group was 61.49%, and the control group was 44.89%, idle group was 41.52%, which was increasing oberviously. The S-phase cells in the experimental group was 28.58%, compared with the 47.36% and 46. 10% diminished. The results of transwell showed that the experimental group had 16. 5000±6. 62076 cells and the other two groups had 45. 6333 13. 54159 and 36. 8333±5. 68412 cells, which showed the invasive power of experimental group was significantly declined(P<0.05).Conclusions It's successful to obtain shRNA sequences that can stably block the expression of p65 in the prostate cancer cell line LNCaP and construct the lentivirus vector. p65 can positively regulates the biological behavior of prostate cancer LNCaP cell line in the cell growth, migration and invasive power.  相似文献   

20.
缓退瘤治疗前列腺癌   总被引:4,自引:0,他引:4  
目的:探讨缓退瘤(Flutamide)与手术或药物去势联合治疗前列腺癌的疗效。方法:回顾性分析18例手术或药物去势联合缓退瘤治疗的前列腺癌患者的临床资料。结果:病理确诊后14例行手术去势及缓退瘤治疗,4例行药物去势加缓退瘤治疗,16例获得显著效果,1例出现肝功能损害,1例出现缓退瘤撤除综合征。  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号